CUSIP 45258H106 · who reports it, how much, and how much it matters to them
18 of the 720 hedge fund managers we track reported shares of Immix Biopharma, Inc. (Nasdaq: IMMX) on Form 13F for 30 June 2026. Between them they reported USD 125m. The largest position belongs to Deep Track Capital, at USD 29m. The manager with the most riding on it is Great Point Partners, where it is 2.5% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Deep Track Capital1 fund on PPLI.com | USD 29m | 0.4% |
| 2 | Millennium Management6 funds on PPLI.com | USD 21m | 0.0% |
| 3 | Marshall Wace LLP84 funds on PPLI.com | USD 19m | 0.0% |
| 4 | Great Point Partners2 funds on PPLI.com | USD 13m | 2.5% |
| 5 | Logos Global Management1 fund on PPLI.com | USD 10m | 0.4% |
| 6 | Bleichroeder4 funds on PPLI.com | USD 10m | 1.8% |
| 7 | Burkehill Global Management5 funds on PPLI.com | USD 5.6m | 0.2% |
| 8 | Citadel Advisors32 funds on PPLI.com | USD 5.2m | 0.0% |
| 9 | Balyasny Asset Management25 funds on PPLI.com | USD 4.3m | 0.0% |
| 10 | Sphera Funds Management1 fund on PPLI.com | USD 2.8m | 0.4% |
| 11 | J. Goldman & Co.1 fund on PPLI.com | USD 2m | 0.1% |
| 12 | D. E. Shaw & Co.15 funds on PPLI.com | USD 960,000 | 0.0% |
| 13 | Squarepoint Ops7 funds on PPLI.com | USD 722,000 | 0.0% |
| 14 | Two Sigma Investments35 funds on PPLI.com | USD 414,000 | 0.0% |
| 15 | Engineers Gate Manager1 fund on PPLI.com | USD 184,000 | 0.0% |
| 16 | Scientech Research2 funds on PPLI.com | USD 139,000 | 0.1% |
| 17 | Magnetar Financial93 funds on PPLI.com | USD 113,000 | 0.0% |
| 18 | The Quarry1 fund on PPLI.com | USD 1,155 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Great Point Partners | USD 13m | 2.5% |
| 2 | Bleichroeder | USD 10m | 1.8% |
| 3 | Logos Global Management | USD 10m | 0.4% |
| 4 | Deep Track Capital | USD 29m | 0.4% |
| 5 | Sphera Funds Management | USD 2.8m | 0.4% |
| 6 | Burkehill Global Management | USD 5.6m | 0.2% |
| 7 | Scientech Research | USD 139,000 | 0.1% |
| 8 | J. Goldman & Co. | USD 2m | 0.1% |
| 9 | Marshall Wace LLP | USD 19m | 0.0% |
| 10 | Millennium Management | USD 21m | 0.0% |
Immix Biopharma, Inc. trades under the symbol IMMX on the Nasdaq. Its CUSIP, the code used on Form 13F, is 45258H106.
18 of the 720 hedge fund managers PPLI.com tracks reported Immix Biopharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Deep Track Capital (USD 29m), Millennium Management (USD 21m), Marshall Wace LLP (USD 19m), Great Point Partners (USD 13m) and Logos Global Management (USD 10m).
18 managers in our coverage reported it, and between them they run 316 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Great Point Partners, where the position was 2.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Immix Biopharma, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.